Reports
Sale
Global Recombinant Vaccines Market: Share, Size, Trends, Growth, Report, Forecast: By Type: Live Attenuated, Subunit; By Disease Indication: Hepatitis B, Rotavirus, Herpes Zoster, Meningococcal B, Others; By Distribution Channel: Hospitals, Vaccination Centres; By End User: Paediatrics, Others; Regional Analysis; Supplier Landscape; 2024-2032
Global Recombinant Vaccines Market Outlook
The value of the global recombinant vaccine market was USD 14.91 billion in 2023, driven by the technological advancements in vaccine development across the globe. The market value is expected to grow at a CAGR of 11.9% during the forecast period of 2024-2032 to reach a value of USD 41.04 billion by 2032.
Key Trends in the Market
Recombinant vaccines are vaccines made with DNA recombination, primarily based on yeast or bacterial cells that are embedded into the host cell to trigger an immune response. Some examples of recombinant vaccines are vaccines against meningitis, hepatitis B, and Influenza B diseases. Recombinant vaccines are less risky, can be produced easily and are also capable of being inserted into multiple carriers.
- Rapid increase in the number of people affected by the zoonotic diseases such as plague, rabies, zoonotic influenza, among other diseases, is expected to increase the demand for recombinant vaccines, fuelling the market growth.
- Key players have been constantly carrying out research and developments for recombinant vaccines with improved protective abilities which is expected to help in the growth of the market.
- Reduced hospital expenditure and reduced side effects of using the recombinant vaccines in comparison to other vaccines has increased its use and demand contributing to the growth of the recombinant vaccines market.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
Based on type, the market can be bifurcated into live attenuated and subunit. By disease indication, the market is divided into hepatitis B, rotavirus, herpes zoster, and meningococcal B, among others. On the basis of end use, the market is segmented into paediatrics, adults, and veterinary. By region, the market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global recombinant vaccines market covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.
- GSK plc
- Pfizer Inc.
- Sanofi
- Walvax Biotechnology Co., Ltd. (Walvax)
- Dynavax Technologies Corporation
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Share by Type
Subunit types of recombinant vaccines are expected to hold a substantial share in the recombinant vaccines market because it does not contain whole virus or bacteria. Containing specific antigens helps these vaccines focus on a small number of antigens. It might require the person to take repeated doses but is considered safer to use in comparison to live attenuated vaccine.
Live attenuated recombinant vaccines contain weakened forms of the virus they protect against. Although they provide long-lasting effects, they may not be suitable for people with weak immune systems. In people with weak immune systems, live attenuated recombinant vaccines risk causing the disease.
Market Share by End Use
Adult end users are a leading shareholder in the recombinant vaccines market because of increasing number of adult patients that are proactively protecting themselves from infectious diseases. This has increased the demand for recombinant vaccine to protect against diseases other vaccine do not prevent, thereby increasing its production. Due to the strong nature of recombinant vaccines, it is safer to give them to adults that can monitor and report any side effects, and have relatively stronger immune systems as compared to children. With new recombinant vaccines released, adults have a wider option to choose from.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Competitive Landscape
GSK plc is pharmaceutical and biotechnology company that has its headquarter in Brentford, United Kingdom. It was founded in 2000 and manufactures specialty medicines along with innovative vaccines for the prevention and treatment of diseases.
Pfizer Inc. founded in 1849 is headquartered in New York, United States. It is a specialised biotechnology and pharmaceutical company that develop and sell vaccines, medical devices, medicines, and healthcare products for treating diseases.
Sanofi was established in 2004 and is based out of Paris, France. A pharmaceutical and healthcare company, it aims to fulfil the health needs of people. They manufacture and sell various health products including vaccines and medicines.
Other market players include Walvax Biotechnology Co., Ltd. (Walvax), and Dynavax Technologies Corporation, among others.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Disease Indication |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Recombinant Vaccine Market Overview
3.1 Global Recombinant Vaccine Market Historical Value (2017-2023)
3.2 Global Recombinant Vaccine Market Forecast Value (2024-2032)
4 Global Recombinant Vaccine Market Landscape
4.1 Global Recombinant Vaccine Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Recombinant Vaccine Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Disease Indication
4.2.3 Analysis by Distribution Channel
4.2.4 Analysis by End User
5 Global Recombinant Vaccine Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Recombinant Vaccine Market Segmentation
6.1 Global Recombinant Vaccine Market by Type
6.1.1 Market Overview
6.1.2 Live Attenuated
6.1.3 Subunit
6.2 Global Recombinant Vaccine Market by Disease Indication
6.2.1 Market Overview
6.2.2 Hepatitis B
6.2.3 Rotavirus
6.2.4 Herpes Zoster
6.2.5 Meningococcal B
6.2.6 Others
6.3 Global Recombinant Vaccine Market by Distribution Channel
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Vaccination Centres
6.4 Global Recombinant Vaccine Market by End User
6.4.1 Market Overview
6.4.2 Paediatrics
6.4.3 Adults
6.4.4 Veterinary
6.5 Global Recombinant Vaccine Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Recombinant Vaccine Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Recombinant Vaccine Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Recombinant Vaccine Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Recombinant Vaccine Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Recombinant Vaccine Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 GSK plc
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Pfizer Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Sanofi
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Walvax Biotechnology Co., Ltd. (Walvax)
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Dynavax Technologies Corporation
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Merck & Co., Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Novartis AG
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 GC Biopharma
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Bayer AG
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Bharat Biotech
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Sartorius AG
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Serum Institute of India Pvt. Ltd.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Bio Farma
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
18 Global Recombinant Vaccine Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The global market size for recombinant vaccines reached a value of more than USD 14.91 billion in 2023.
The market is expected to grow at a CAGR of 11.9% between 2024 and 2032.
The major market drivers include increasing awareness, improved availability of recombinant vaccines, and spread of infectious diseases.
The global market size for recombinant vaccines is expected to reach a value of more than USD 41.04 billion by 2032.
The key trends of the market are advantages of recombinant vaccines, research and development by key players, and reduced expenditure and side effects of these vaccines.
Key market players include GSK plc, Pfizer Inc., Sanofi, Walvax Biotechnology Co., Ltd. (Walvax), and Dynavax Technologies Corporation, among others.
Recombinant vaccines are made with DNA recombination of yeast or bacterial cells that are embedded into the host cell to trigger an immune response.
Some examples of recombinant vaccines are vaccines against meningitis, hepatitis B, and Influenza B diseases.
The global recombinant vaccines market is segmented based on type, disease indication, end use, and region.
Recombinant vaccines are less risky, can be produced easily and are also capable of being inserted into multiple carriers.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER